Relafen 750 mg, a noncopyrightal anti-inflammatory drug (NSAID), displays significant biochemical attributes that contribute to its therapeutic effectiveness. A comprehensive analysis of these properties reveals valuable insights into the mechanism of action and potential clinical implications. The drug's primary target is the inhibition of cycloox